PT  - JOURNAL ARTICLE
AU  - Le, Phuc
AU  - Sabella, Camille
AU  - Rothberg, Michael B.
TI  - Preventing herpes zoster through vaccination: New developments
AID  - 10.3949/ccjm.84a.16020
DP  - 2017 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 359--366
VI  - 84
IP  - 5
4099  - http://www.ccjm.org/content/84/5/359.short
4100  - http://www.ccjm.org/content/84/5/359.full
SO  - Cleve Clin J Med2017 May 01; 84
AB  - Herpes zoster (HZ) affects 1 million Americans every year. The disease burden is higher in immunocompromised patients. The live-attenuated HZ vaccine is effective in preventing HZ and postherpetic neuralgia and has been recommended for immunocompetent adults age 60 and older. However, because protection wanes by 10 years, a booster may be necessary. In 2015, an adjuvanted subunit HZ vaccine was shown to reduce incidence by 97%, even in the elderly, but long-term data on vaccine protection are not available. Clinical trials are under way to investigate a safe and effective vaccine for immunocompromised patients.